

FIRST REGULAR SESSION

# SENATE BILL NO. 120

99TH GENERAL ASSEMBLY

---

INTRODUCED BY SENATOR SCHAAF.

---

Pre-filed December 1, 2016, and ordered printed.

ADRIANE D. CROUSE, Secretary.

0663S.01I

---

## AN ACT

To repeal section 195.010 and 195.017, RSMo, and to enact in lieu thereof six new sections relating to industrial hemp, with penalty provisions.

---

*Be it enacted by the General Assembly of the State of Missouri, as follows:*

---

Section A. Sections 195.010 and 195.017, RSMo, are repealed and six new  
2 sections enacted in lieu thereof, to be known as sections 195.010, 195.017,  
3 195.600, 195.603, 195.606, and 195.609, to read as follows:

195.010. The following words and phrases as used in this chapter and  
2 chapter 579, unless the context otherwise requires, mean:

3 (1) "Addict", a person who habitually uses one or more controlled  
4 substances to such an extent as to create a tolerance for such drugs, and who does  
5 not have a medical need for such drugs, or who is so far addicted to the use of  
6 such drugs as to have lost the power of self-control with reference to his or her  
7 addiction;

8 (2) "Administer", to apply a controlled substance, whether by injection,  
9 inhalation, ingestion, or any other means, directly to the body of a patient or  
10 research subject by:

11 (a) A practitioner (or, in his or her presence, by his or her authorized  
12 agent); or

13 (b) The patient or research subject at the direction and in the presence of  
14 the practitioner;

15 (3) "Agent", an authorized person who acts on behalf of or at the direction  
16 of a manufacturer, distributor, or dispenser. The term does not include a common  
17 or contract carrier, public warehouseman, or employee of the carrier or  
18 warehouseman while acting in the usual and lawful course of the carrier's or

**EXPLANATION—Matter enclosed in bold-faced brackets [thus] in this bill is not enacted and is intended to be omitted in the law.**

19 warehouseman's business;

20 (4) "Attorney for the state", any prosecuting attorney, circuit attorney, or  
21 attorney general authorized to investigate, commence and prosecute an action  
22 under this chapter;

23 (5) "Controlled substance", a drug, substance, or immediate precursor in  
24 Schedules I through V listed in this chapter;

25 (6) "Controlled substance analogue", a substance the chemical structure  
26 of which is substantially similar to the chemical structure of a controlled  
27 substance in Schedule I or II and:

28 (a) Which has a stimulant, depressant, or hallucinogenic effect on the  
29 central nervous system substantially similar to the stimulant, depressant, or  
30 hallucinogenic effect on the central nervous system of a controlled substance  
31 included in Schedule I or II; or

32 (b) With respect to a particular individual, which that individual  
33 represents or intends to have a stimulant, depressant, or hallucinogenic effect on  
34 the central nervous system substantially similar to the stimulant, depressant, or  
35 hallucinogenic effect on the central nervous system of a controlled substance  
36 included in Schedule I or II. The term does not include a controlled substance;  
37 any substance for which there is an approved new drug application; any  
38 substance for which an exemption is in effect for investigational use, for a  
39 particular person, under Section 505 of the federal Food, Drug and Cosmetic Act  
40 (21 U.S.C. Section 355) to the extent conduct with respect to the substance is  
41 pursuant to the exemption; or any substance to the extent not intended for  
42 human consumption before such an exemption takes effect with respect to the  
43 substance;

44 (7) "Counterfeit substance", a controlled substance which, or the container  
45 or labeling of which, without authorization, bears the trademark, trade name, or  
46 other identifying mark, imprint, number or device, or any likeness thereof, of a  
47 manufacturer, distributor, or dispenser other than the person who in fact  
48 manufactured, distributed, or dispensed the substance;

49 (8) "Deliver" or "delivery", the actual, constructive, or attempted transfer  
50 from one person to another of drug paraphernalia or of a controlled substance, or  
51 an imitation controlled substance, whether or not there is an agency relationship,  
52 and includes a sale;

53 (9) "Dentist", a person authorized by law to practice dentistry in this  
54 state;

55 (10) "Depressant or stimulant substance":

56 (a) A drug containing any quantity of barbituric acid or any of the salts  
57 of barbituric acid or any derivative of barbituric acid which has been designated  
58 by the United States Secretary of Health and Human Services as habit forming  
59 under 21 U.S.C. Section 352(d);

60 (b) A drug containing any quantity of:

61 a. Amphetamine or any of its isomers;

62 b. Any salt of amphetamine or any salt of an isomer of amphetamine; or

63 c. Any substance the United States Attorney General, after investigation,  
64 has found to be, and by regulation designated as, habit forming because of its  
65 stimulant effect on the central nervous system;

66 (c) Lysergic acid diethylamide; or

67 (d) Any drug containing any quantity of a substance that the United  
68 States Attorney General, after investigation, has found to have, and by regulation  
69 designated as having, a potential for abuse because of its depressant or stimulant  
70 effect on the central nervous system or its hallucinogenic effect;

71 (11) "Dispense", to deliver a narcotic or controlled dangerous drug to an  
72 ultimate user or research subject by or pursuant to the lawful order of a  
73 practitioner including the prescribing, administering, packaging, labeling, or  
74 compounding necessary to prepare the substance for such delivery. "Dispenser"  
75 means a practitioner who dispenses;

76 (12) "Distribute", to deliver other than by administering or dispensing a  
77 controlled substance;

78 (13) "Distributor", a person who distributes;

79 (14) "Drug":

80 (a) Substances recognized as drugs in the official United States  
81 Pharmacopoeia, Official Homeopathic Pharmacopoeia of the United States, or  
82 Official National Formulary, or any supplement to any of them;

83 (b) Substances intended for use in the diagnosis, cure, mitigation,  
84 treatment or prevention of disease in humans or animals;

85 (c) Substances, other than food, intended to affect the structure or any  
86 function of the body of humans or animals; and

87 (d) Substances intended for use as a component of any article specified in  
88 this subdivision. It does not include devices or their components, parts or  
89 accessories;

90 (15) "Drug-dependent person", a person who is using a controlled

91 substance and who is in a state of psychic or physical dependence, or both, arising  
92 from the use of such substance on a continuous basis. Drug dependence is  
93 characterized by behavioral and other responses which include a strong  
94 compulsion to take the substance on a continuous basis in order to experience its  
95 psychic effects or to avoid the discomfort caused by its absence;

96 (16) "Drug enforcement agency", the Drug Enforcement Administration in  
97 the United States Department of Justice, or its successor agency;

98 (17) "Drug paraphernalia", all equipment, products, substances and  
99 materials of any kind which are used, intended for use, or designed for use, in  
100 planting, propagating, cultivating, growing, harvesting, manufacturing,  
101 compounding, converting, producing, processing, preparing, storing, containing,  
102 concealing, injecting, ingesting, inhaling, or otherwise introducing into the human  
103 body a controlled substance or an imitation controlled substance in violation of  
104 this chapter or chapter 579. It includes, but is not limited to:

105 (a) Kits used, intended for use, or designed for use in planting,  
106 propagating, cultivating, growing or harvesting of any species of plant which is  
107 a controlled substance or from which a controlled substance can be derived;

108 (b) Kits used, intended for use, or designed for use in manufacturing,  
109 compounding, converting, producing, processing, or preparing controlled  
110 substances or imitation controlled substances;

111 (c) Isomerization devices used, intended for use, or designed for use in  
112 increasing the potency of any species of plant which is a controlled substance or  
113 an imitation controlled substance;

114 (d) Testing equipment used, intended for use, or designed for use in  
115 identifying, or in analyzing the strength, effectiveness or purity of controlled  
116 substances or imitation controlled substances;

117 (e) Scales and balances used, intended for use, or designed for use in  
118 weighing or measuring controlled substances or imitation controlled substances;

119 (f) Dilutents and adulterants, such as quinine hydrochloride, mannitol,  
120 mannite, dextrose and lactose, used, intended for use, or designed for use in  
121 cutting controlled substances or imitation controlled substances;

122 (g) Separation gins and sifters used, intended for use, or designed for use  
123 in removing twigs and seeds from, or in otherwise cleaning or refining,  
124 marijuana;

125 (h) Blenders, bowls, containers, spoons and mixing devices used, intended  
126 for use, or designed for use in compounding controlled substances or imitation

127 controlled substances;

128 (i) Capsules, balloons, envelopes and other containers used, intended for  
129 use, or designed for use in packaging small quantities of controlled substances or  
130 imitation controlled substances;

131 (j) Containers and other objects used, intended for use, or designed for use  
132 in storing or concealing controlled substances or imitation controlled substances;

133 (k) Hypodermic syringes, needles and other objects used, intended for use,  
134 or designed for use in parenterally injecting controlled substances or imitation  
135 controlled substances into the human body;

136 (l) Objects used, intended for use, or designed for use in ingesting,  
137 inhaling, or otherwise introducing marijuana, cocaine, hashish, or hashish oil into  
138 the human body, such as:

139 a. Metal, wooden, acrylic, glass, stone, plastic, or ceramic pipes with or  
140 without screens, permanent screens, hashish heads, or punctured metal bowls;

141 b. Water pipes;

142 c. Carburetion tubes and devices;

143 d. Smoking and carburetion masks;

144 e. Roach clips meaning objects used to hold burning material, such as a  
145 marijuana cigarette, that has become too small or too short to be held in the  
146 hand;

147 f. Miniature cocaine spoons and cocaine vials;

148 g. Chamber pipes;

149 h. Carburetor pipes;

150 i. Electric pipes;

151 j. Air-driven pipes;

152 k. Chillums;

153 l. Bongs;

154 m. Ice pipes or chillers;

155 (m) Substances used, intended for use, or designed for use in the  
156 manufacture of a controlled substance;

157 In determining whether an object, product, substance or material is drug  
158 paraphernalia, a court or other authority should consider, in addition to all other  
159 logically relevant factors, the following:

160 a. Statements by an owner or by anyone in control of the object concerning  
161 its use;

162 b. Prior convictions, if any, of an owner, or of anyone in control of the

163 object, under any state or federal law relating to any controlled substance or  
164 imitation controlled substance;

165 c. The proximity of the object, in time and space, to a direct violation of  
166 this chapter or chapter 579;

167 d. The proximity of the object to controlled substances or imitation  
168 controlled substances;

169 e. The existence of any residue of controlled substances or imitation  
170 controlled substances on the object;

171 f. Direct or circumstantial evidence of the intent of an owner, or of anyone  
172 in control of the object, to deliver it to persons who he or she knows, or should  
173 reasonably know, intend to use the object to facilitate a violation of this chapter  
174 or chapter 579; the innocence of an owner, or of anyone in control of the object,  
175 as to direct violation of this chapter or chapter 579 shall not prevent a finding  
176 that the object is intended for use, or designed for use as drug paraphernalia;

177 g. Instructions, oral or written, provided with the object concerning its  
178 use;

179 h. Descriptive materials accompanying the object which explain or depict  
180 its use;

181 i. National or local advertising concerning its use;

182 j. The manner in which the object is displayed for sale;

183 k. Whether the owner, or anyone in control of the object, is a legitimate  
184 supplier of like or related items to the community, such as a licensed distributor  
185 or dealer of tobacco products;

186 l. Direct or circumstantial evidence of the ratio of sales of the object to the  
187 total sales of the business enterprise;

188 m. The existence and scope of legitimate uses for the object in the  
189 community;

190 n. Expert testimony concerning its use;

191 o. The quantity, form or packaging of the product, substance or material  
192 in relation to the quantity, form or packaging associated with any legitimate use  
193 for the product, substance or material;

194 (18) "Federal narcotic laws", the laws of the United States relating to  
195 controlled substances;

196 (19) "Hospital", a place devoted primarily to the maintenance and  
197 operation of facilities for the diagnosis, treatment or care, for not less than  
198 twenty-four hours in any week, of three or more nonrelated individuals suffering

199 from illness, disease, injury, deformity or other abnormal physical conditions; or  
200 a place devoted primarily to provide, for not less than twenty-four consecutive  
201 hours in any week, medical or nursing care for three or more nonrelated  
202 individuals. The term "hospital" does not include convalescent, nursing, shelter  
203 or boarding homes as defined in chapter 198;

204 (20) "Immediate precursor", a substance which:

205 (a) The state department of health and senior services has found to be and  
206 by rule designates as being the principal compound commonly used or produced  
207 primarily for use in the manufacture of a controlled substance;

208 (b) Is an immediate chemical intermediary used or likely to be used in the  
209 manufacture of a controlled substance; and

210 (c) The control of which is necessary to prevent, curtail or limit the  
211 manufacture of the controlled substance;

212 (21) "Imitation controlled substance", a substance that is not a controlled  
213 substance, which by dosage unit appearance (including color, shape, size and  
214 markings), or by representations made, would lead a reasonable person to believe  
215 that the substance is a controlled substance. In determining whether the  
216 substance is an imitation controlled substance the court or authority concerned  
217 should consider, in addition to all other logically relevant factors, the following:

218 (a) Whether the substance was approved by the federal Food and Drug  
219 Administration for over-the-counter (nonprescription or nonlegend) sales and was  
220 sold in the federal Food and Drug Administration approved package, with the  
221 federal Food and Drug Administration approved labeling information;

222 (b) Statements made by an owner or by anyone else in control of the  
223 substance concerning the nature of the substance, or its use or effect;

224 (c) Whether the substance is packaged in a manner normally used for  
225 illicit controlled substances;

226 (d) Prior convictions, if any, of an owner, or anyone in control of the  
227 object, under state or federal law related to controlled substances or fraud;

228 (e) The proximity of the substances to controlled substances;

229 (f) Whether the consideration tendered in exchange for the noncontrolled  
230 substance substantially exceeds the reasonable value of the substance considering  
231 the actual chemical composition of the substance and, where applicable, the price  
232 at which over-the-counter substances of like chemical composition sell. An  
233 imitation controlled substance does not include a placebo or registered  
234 investigational drug either of which was manufactured, distributed, possessed or

235 delivered in the ordinary course of professional practice or research;

236 (22) **"Industrial hemp":**

237 (a) **All nonseed parts and varieties of the cannabis sativa plant,**  
238 **growing or not, that contain a cropwide average tetrahydrocannabinol**  
239 **(THC) concentration that does not exceed three-tenths of one percent**  
240 **on a dry weight basis; or**

241 (b) **Any cannabis sativa seed that is part of a growing crop,**  
242 **retained by a grower for future planting, or used for processing into or**  
243 **use as agricultural hemp seed.**

244 **Industrial hemp does not include industrial hemp commodities and**  
245 **products;**

246 (23) "Laboratory", a laboratory approved by the department of health and  
247 senior services as proper to be entrusted with the custody of controlled substances  
248 but does not include a pharmacist who compounds controlled substances to be  
249 sold or dispensed on prescriptions;

250 [(23)] (24) "Manufacture", the production, preparation, propagation,  
251 compounding or processing of drug paraphernalia or of a controlled substance, or  
252 an imitation controlled substance, either directly or by extraction from substances  
253 of natural origin, or independently by means of chemical synthesis, or by a  
254 combination of extraction and chemical synthesis, and includes any packaging or  
255 repackaging of the substance or labeling or relabeling of its container. This term  
256 does not include the preparation or compounding of a controlled substance or an  
257 imitation controlled substance or the preparation, compounding, packaging or  
258 labeling of a narcotic or dangerous drug:

259 (a) By a practitioner as an incident to his or her administering or  
260 dispensing of a controlled substance or an imitation controlled substance in the  
261 course of his or her professional practice, or

262 (b) By a practitioner or his or her authorized agent under his or her  
263 supervision, for the purpose of, or as an incident to, research, teaching or  
264 chemical analysis and not for sale;

265 [(24)] (25) "Marijuana", all parts of the plant genus Cannabis in any  
266 species or form thereof, including, but not limited to Cannabis Sativa L., **except**  
267 **industrial hemp as defined in this section**, Cannabis Indica, Cannabis  
268 Americana, Cannabis Ruderalis, and Cannabis Gigantea, whether growing or not,  
269 the seeds thereof, the resin extracted from any part of the plant; and every  
270 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its



271 seeds or resin. It does not include the mature stalks of the plant, fiber produced  
272 from the stalks, oil or cake made from the seeds of the plant, any other  
273 compound, manufacture, salt, derivative, mixture or preparation of the mature  
274 stalks (except the resin extracted therefrom), fiber, oil or cake, or the sterilized  
275 seed of the plant which is incapable of germination;

276 [(25)] (26) "Methamphetamine precursor drug", any drug containing  
277 ephedrine, pseudoephedrine, phenylpropanolamine, or any of their salts, optical  
278 isomers, or salts of optical isomers;

279 [(26)] (27) "Narcotic drug", any of the following, whether produced  
280 directly or indirectly by extraction from substances of vegetable origin, or  
281 independently by means of chemical synthesis, or by a combination of extraction  
282 and chemical analysis:

283 (a) Opium, opiate, and any derivative, of opium or opiate, including their  
284 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever  
285 the existence of the isomers, esters, ethers, and salts is possible within the  
286 specific chemical designation. The term does not include the isoquinoline  
287 alkaloids of opium;

288 (b) Coca leaves, but not including extracts of coca leaves from which  
289 cocaine, ecgonine, and derivatives of ecgonine or their salts have been removed;

290 (c) Cocaine or any salt, isomer, or salt of isomer thereof;

291 (d) Ecgonine, or any derivative, salt, isomer, or salt of isomer thereof;

292 (e) Any compound, mixture, or preparation containing any quantity of any  
293 substance referred to in paragraphs (a) to (d) of this subdivision;

294 [(27)] (28) "Official written order", an order written on a form provided  
295 for that purpose by the United States Commissioner of Narcotics, under any laws  
296 of the United States making provision therefor, if such order forms are authorized  
297 and required by federal law, and if no such order form is provided, then on an  
298 official form provided for that purpose by the department of health and senior  
299 services;

300 [(28)] (29) "Opiate", any substance having an addiction-forming or  
301 addiction-sustaining liability similar to morphine or being capable of conversion  
302 into a drug having addiction-forming or addiction-sustaining liability. The term  
303 includes its racemic and levorotatory forms. It does not include, unless  
304 specifically controlled under section 195.017, the dextrorotatory isomer of  
305 3-methoxy-n-methyl-morphinan and its salts (dextromethorphan);

306 [(29)] (30) "Opium poppy", the plant of the species *Papaver somniferum*

307 L., except its seeds;

308 [(30)] (31) "Over-the-counter sale", a retail sale licensed pursuant to  
309 chapter 144 of a drug other than a controlled substance;

310 [(31)] (32) "Person", an individual, corporation, government or  
311 governmental subdivision or agency, business trust, estate, trust, partnership,  
312 joint venture, association, or any other legal or commercial entity;

313 [(32)] (33) "Pharmacist", a licensed pharmacist as defined by the laws of  
314 this state, and where the context so requires, the owner of a store or other place  
315 of business where controlled substances are compounded or dispensed by a  
316 licensed pharmacist; but nothing in this chapter shall be construed as conferring  
317 on a person who is not registered nor licensed as a pharmacist any authority,  
318 right or privilege that is not granted to him by the pharmacy laws of this state;

319 [(33)] (34) "Poppy straw", all parts, except the seeds, of the opium poppy,  
320 after mowing;

321 [(34)] (35) "Possessed" or "possessing a controlled substance", a person,  
322 with the knowledge of the presence and nature of a substance, has actual or  
323 constructive possession of the substance. A person has actual possession if he has  
324 the substance on his or her person or within easy reach and convenient control.  
325 A person who, although not in actual possession, has the power and the intention  
326 at a given time to exercise dominion or control over the substance either directly  
327 or through another person or persons is in constructive possession of  
328 it. Possession may also be sole or joint. If one person alone has possession of a  
329 substance possession is sole. If two or more persons share possession of a  
330 substance, possession is joint;

331 [(35)] (36) "Practitioner", a physician, dentist, optometrist, podiatrist,  
332 veterinarian, scientific investigator, pharmacy, hospital or other person licensed,  
333 registered or otherwise permitted by this state to distribute, dispense, conduct  
334 research with respect to or administer or to use in teaching or chemical analysis,  
335 a controlled substance in the course of professional practice or research in this  
336 state, or a pharmacy, hospital or other institution licensed, registered, or  
337 otherwise permitted to distribute, dispense, conduct research with respect to or  
338 administer a controlled substance in the course of professional practice or  
339 research;

340 [(36)] (37) "Production", includes the manufacture, planting, cultivation,  
341 growing, or harvesting of drug paraphernalia or of a controlled substance or an  
342 imitation controlled substance;

343           [(37)] **(38)** "Registry number", the number assigned to each person  
344 registered under the federal controlled substances laws;

345           [(38)] **(39)** "Sale", includes barter, exchange, or gift, or offer therefor, and  
346 each such transaction made by any person, whether as principal, proprietor,  
347 agent, servant or employee;

348           [(39)] **(40)** "State" when applied to a part of the United States, includes  
349 any state, district, commonwealth, territory, insular possession thereof, and any  
350 area subject to the legal authority of the United States of America;

351           [(40)] **(41)** "Synthetic cannabinoid", includes unless specifically excepted  
352 or unless listed in another schedule, any natural or synthetic material, compound,  
353 mixture, or preparation that contains any quantity of a substance that is a  
354 cannabinoid receptor agonist, including but not limited to any substance listed  
355 in paragraph (ll) of subdivision (4) of subsection 2 of section 195.017 and any  
356 analogues; homologues; isomers, whether optical, positional, or geometric; esters;  
357 ethers; salts; and salts of isomers, esters, and ethers, whenever the existence of  
358 the isomers, esters, ethers, or salts is possible within the specific chemical  
359 designation, however, it shall not include any approved pharmaceutical  
360 authorized by the United States Food and Drug Administration;

361           [(41)] **(42)** "Ultimate user", a person who lawfully possesses a controlled  
362 substance or an imitation controlled substance for his or her own use or for the  
363 use of a member of his or her household or immediate family, regardless of  
364 whether they live in the same household, or for administering to an animal owned  
365 by him or by a member of his or her household. For purposes of this section, the  
366 phrase "immediate family" means a husband, wife, parent, child, sibling,  
367 stepparent, stepchild, stepbrother, stepsister, grandparent, or grandchild;

368           [(42)] **(43)** "Wholesaler", a person who supplies drug paraphernalia or  
369 controlled substances or imitation controlled substances that he himself has not  
370 produced or prepared, on official written orders, but not on prescriptions.

195.017. 1. The department of health and senior services shall place a  
2 substance in Schedule I if it finds that the substance:

3           (1) Has high potential for abuse; and

4           (2) Has no accepted medical use in treatment in the United States or  
5 lacks accepted safety for use in treatment under medical supervision.

6           2. Schedule I:

7           (1) The controlled substances listed in this subsection are included in  
8 Schedule I;

9           (2) Any of the following opiates, including their isomers, esters, ethers,  
10 salts, and salts of isomers, esters, and ethers, unless specifically excepted,  
11 whenever the existence of these isomers, esters, ethers and salts is possible  
12 within the specific chemical designation:

- 13           (a) Acetyl-alpha-methylfentanyl;
- 14           (b) Acetylmethadol;
- 15           (c) Allylprodine;
- 16           (d) Alphacetylmethadol;
- 17           (e) Alphameprodine;
- 18           (f) Alphamethadol;
- 19           (g) Alpha-methylfentanyl;
- 20           (h) Alpha-methylthiofentanyl;
- 21           (i) Benzethidine;
- 22           (j) Betacetylmethadol;
- 23           (k) Beta-hydroxyfentanyl;
- 24           (l) Beta-hydroxy-3-methylfentanyl;
- 25           (m) Betameprodine;
- 26           (n) Betamethadol;
- 27           (o) Betaprodine;
- 28           (p) Clonitazene;
- 29           (q) Dextromoramide;
- 30           (r) Diampromide;
- 31           (s) Diethylthiambutene;
- 32           (t) Difenoxin;
- 33           (u) Dimenoxadol;
- 34           (v) Dimepheptanol;
- 35           (w) Dimethylthiambutene;
- 36           (x) Dioxaphetyl butyrate;
- 37           (y) Dipipanone;
- 38           (z) Ethylmethylthiambutene;
- 39           (aa) Etonitazene;
- 40           (bb) Etoxidine;
- 41           (cc) Furethidine;
- 42           (dd) Hydroxypethidine;
- 43           (ee) Ketobemidone;
- 44           (ff) Levomoramide;

- 45 (gg) Levophenacymorphan;  
46 (hh) 3-Methylfentanyl;  
47 (ii) 3-Methylthiofentanyl;  
48 (jj) Morpheridine;  
49 (kk) MPPP;  
50 (ll) Noracymethadol;  
51 (mm) Norlevorphanol;  
52 (nn) Normethadone;  
53 (oo) Norpipanone;  
54 (pp) Para-fluorofentanyl;  
55 (qq) PEPAP;  
56 (rr) Phenadoxone;  
57 (ss) Phenampromide;  
58 (tt) Phenomorphan;  
59 (uu) Phenoperidine;  
60 (vv) Piritramide;  
61 (ww) Proheptazine;  
62 (xx) Properidine;  
63 (yy) Propiram;  
64 (zz) Racemoramide;  
65 (aaa) Thiofentanyl;  
66 (bbb) Tilidine;  
67 (ccc) Trimeperidine;  
68 (3) Any of the following opium derivatives, their salts, isomers and salts  
69 of isomers unless specifically excepted, whenever the existence of these salts,  
70 isomers and salts of isomers is possible within the specific chemical designation:  
71 (a) Acetorphine;  
72 (b) Acetyldihydrocodeine;  
73 (c) Benzylmorphine;  
74 (d) Codeine methylbromide;  
75 (e) Codeine-N-Oxide;  
76 (f) Cyprenorphine;  
77 (g) Desomorphine;  
78 (h) Dihydromorphine;  
79 (i) Drotebanol;  
80 (j) Etorphine (except hydrochloride salt);

- 81 (k) Heroin;
- 82 (l) Hydromorphenol;
- 83 (m) Methyldesorphine;
- 84 (n) Methyldihydromorphine;
- 85 (o) Morphine methylbromide;
- 86 (p) Morphine methylsulfonate;
- 87 (q) Morphine-N-Oxide;
- 88 (r) Myrophine;
- 89 (s) Nicocodeine;
- 90 (t) Nicomorphine;
- 91 (u) Normorphine;
- 92 (v) Pholcodine;
- 93 (w) Thebacon;
- 94 (4) Any material, compound, mixture or preparation which contains any
- 95 quantity of the following hallucinogenic substances, their salts, isomers and salts
- 96 of isomers, unless specifically excepted, whenever the existence of these salts,
- 97 isomers, and salts of isomers is possible within the specific chemical designation:
- 98 (a) 4-bromo-2, 5-dimethoxyamphetamine;
- 99 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
- 100 (c) 2,5-dimethoxyamphetamine;
- 101 (d) 2,5-dimethoxy-4-ethylamphetamine;
- 102 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 103 (f) 4-methoxyamphetamine;
- 104 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
- 105 (h) 4-methyl-2, 5-dimethoxyamphetamine;
- 106 (i) 3,4-methylenedioxyamphetamine;
- 107 (j) 3,4-methylenedioxymethamphetamine;
- 108 (k) 3,4-methylenedioxy-N-ethylamphetamine;
- 109 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
- 110 (m) 3,4,5-trimethoxyamphetamine;
- 111 (n) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine, its isomers, salts,
- 112 and salts of isomers;
- 113 (o) Alpha-ethyltryptamine;
- 114 (p) Alpha-methyltryptamine;
- 115 (q) Bufotenine;
- 116 (r) Diethyltryptamine;

- 117 (s) Dimethyltryptamine;
- 118 (t) 5-methoxy-N,N-diisopropyltryptamine;
- 119 (u) Ibogaine;
- 120 (v) Lysergic acid diethylamide;
- 121 (w) Marijuana or marihuana, **except industrial hemp as defined in**
- 122 **section 195.010**;
- 123 (x) Mescaline;
- 124 (y) Parahexyl;
- 125 (z) Peyote, to include all parts of the plant presently classified botanically
- 126 as *Lophophora Williamsii* Lemaire, whether growing or not; the seeds thereof; any
- 127 extract from any part of such plant; and every compound, manufacture, salt,
- 128 derivative, mixture or preparation of the plant, its seed or extracts;
- 129 (aa) N-ethyl-3-piperidyl benzilate;
- 130 (bb) N-methyl-3-piperidyl benzilate;
- 131 (cc) Psilocybin;
- 132 (dd) Psilocyn;
- 133 (ee) Tetrahydrocannabinols naturally contained in a plant of the genus
- 134 *Cannabis* (cannabis plant), **except industrial hemp as defined in section**
- 135 **195.010**, as well as synthetic equivalents of the substances contained in the
- 136 cannabis plant, or in the resinous extractives of such plant, or synthetic
- 137 substances, derivatives, and their isomers with similar chemical structure and
- 138 pharmacological activity to those substances contained in the plant, such as the
- 139 following:
- 140 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;
- 141 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;
- 142 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;
- 143 d. Any compounds of these structures, regardless of numerical designation
- 144 of atomic positions covered;
- 145 (ff) Ethylamine analog of phencyclidine;
- 146 (gg) Pyrrolidine analog of phencyclidine;
- 147 (hh) Thiophene analog of phencyclidine;
- 148 (ii) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
- 149 (jj) *Salvia divinorum*;
- 150 (kk) Salvinorin A;
- 151 (ll) Synthetic cannabinoids:
- 152 a. Any compound structurally derived from 3-(1-naphthoyl)indole or

153 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the  
154 indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
155 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not  
156 further substituted in the indole ring to any extent, whether or not substituted  
157 in the naphthyl ring to any extent. Including, but not limited to:

- 158 (i) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;
- 159 (ii) JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole;
- 160 (iii) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;
- 161 (iv) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;
- 162 (v) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;
- 163 (vi) JWH-081, or 1-pentyl-3-(4-methoxy-1-naphthoyl)indole;
- 164 (vii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;
- 165 (viii) JWH-122, or 1-pentyl-3-(4-methyl-1-naphthoyl)indole;
- 166 (ix) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
- 167 (x) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
- 168 (xi) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole;
- 169 (xii) JWH-398, or 1-pentyl-3-(4-chloro-1-naphthoyl)indole;

170 b. Any compound structurally derived from 3-(1-naphthoyl)pyrrole by  
171 substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,  
172 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or  
173 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole  
174 ring to any extent, whether or not substituted in the naphthyl ring to any extent;

175 c. Any compound structurally derived from 1-(1-naphthylmethyl)indene  
176 by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl,  
177 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or  
178 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene  
179 ring to any extent, whether or not substituted in the naphthyl ring to any extent;

180 d. Any compound structurally derived from 3-phenylacetylindole by  
181 substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl,  
182 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or  
183 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole  
184 ring to any extent, whether or not substituted in the phenyl ring to any  
185 extent. Including, but not limited to:

- 186 (i) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole;
- 187 (ii) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole;
- 188 (iii) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole;



- 189 (iv) JWH-251, or 1-pentyl-3-(2-methylphenylacetyl)indole;
- 190 (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole;
- 191 e. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol
- 192 by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl,
- 193 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or
- 194 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring
- 195 to any extent. Including, but not limited to:
- 196 (i) CP 47, 497 & homologues, or 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-
- 197 methyloctan-2-yl)phenol), where side chain n=5, and homologues where side chain
- 198 n-4,6, or 7;
- 199 f. Any compound containing a 3-(benzoyl)indole structure with
- 200 substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl,
- 201 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or
- 202 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole
- 203 ring to any extent and whether or not substituted in the phenyl ring to any
- 204 extent. Including, but not limited to:
- 205 (i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;
- 206 (ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole;
- 207 g. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-
- 208 phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;
- 209 h. HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
- 210 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
- 211 i. HU-211, or Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-
- 212 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
- 213 j. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-
- 214 phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;
- 215 k. Dimethylheptylpyran, or DMHP;
- 216 (5) Any material, compound, mixture or preparation containing any
- 217 quantity of the following substances having a depressant effect on the central
- 218 nervous system, including their salts, isomers and salts of isomers whenever the
- 219 existence of these salts, isomers and salts of isomers is possible within the
- 220 specific chemical designation:
- 221 (a) Gamma-hydroxybutyric acid;
- 222 (b) Mecloqualone;
- 223 (c) Methaqualone;
- 224 (6) Any material, compound, mixture or preparation containing any

225 quantity of the following substances having a stimulant effect on the central  
226 nervous system, including their salts, isomers and salts of isomers:

- 227 (a) Aminorex;
- 228 (b) N-benzylpiperazine;
- 229 (c) Cathinone;
- 230 (d) Fenethylline;
- 231 (e) 3-Fluoromethcathinone;
- 232 (f) 4-Fluoromethcathinone;
- 233 (g) Mephedrone, or 4-methylmethcathinone;
- 234 (h) Methcathinone;
- 235 (i) 4-methoxymethcathinone;
- 236 (j) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl -2-  
237 oxazolamine);
- 238 (k) Methylenedioxypyrovalerone, MDPV, or (1-(1,3-Benzodioxol-5-yl)-2-  
239 (1-pyrrolidinyl)-1-pentanone;
- 240 (l) Methylone, or 3,4-Methylenedioxymethcathinone;
- 241 (m) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP;
- 242 (n) N-ethylamphetamine;
- 243 (o) N,N-dimethylamphetamine;

244 (7) A temporary listing of substances subject to emergency scheduling  
245 under federal law shall include any material, compound, mixture or preparation  
246 which contains any quantity of the following substances:

- 247 (a) N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), its  
248 optical isomers, salts and salts of isomers;
- 249 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide  
250 (thenylfentanyl), its optical isomers, salts and salts of isomers;
- 251 (8) Khat, to include all parts of the plant presently classified botanically  
252 as *catha edulis*, whether growing or not; the seeds thereof; any extract from any  
253 part of such plant; and every compound, manufacture, salt, derivative, mixture,  
254 or preparation of the plant, its seed or extracts.

255 3. The department of health and senior services shall place a substance  
256 in Schedule II if it finds that:

- 257 (1) The substance has high potential for abuse;
- 258 (2) The substance has currently accepted medical use in treatment in the  
259 United States, or currently accepted medical use with severe restrictions; and
- 260 (3) The abuse of the substance may lead to severe psychic or physical

261 dependence.

262 4. The controlled substances listed in this subsection are included in  
263 Schedule II:

264 (1) Any of the following substances whether produced directly or indirectly  
265 by extraction from substances of vegetable origin, or independently by means of  
266 chemical synthesis, or by combination of extraction and chemical synthesis:

267 (a) Opium and opiate and any salt, compound, derivative or preparation  
268 of opium or opiate, excluding apomorphine, thebaine-derived butorphanol,  
269 dextrorphan, nalbuphine, nalmefene, naloxone and naltrexone, and their  
270 respective salts but including the following:

271 a. Raw opium;

272 b. Opium extracts;

273 c. Opium fluid;

274 d. Powdered opium;

275 e. Granulated opium;

276 f. Tincture of opium;

277 g. Codeine;

278 h. Ethylmorphine;

279 i. Etorphine hydrochloride;

280 j. Hydrocodone;

281 k. Hydromorphone;

282 l. Metopon;

283 m. Morphine;

284 n. Oxycodone;

285 o. Oxymorphone;

286 p. Thebaine;

287 (b) Any salt, compound, derivative, or preparation thereof which is  
288 chemically equivalent or identical with any of the substances referred to in this  
289 subdivision, but not including the isoquinoline alkaloids of opium;

290 (c) Opium poppy and poppy straw;

291 (d) Coca leaves and any salt, compound, derivative, or preparation of coca  
292 leaves, and any salt, compound, derivative, or preparation thereof which is  
293 chemically equivalent or identical with any of these substances, but not including  
294 decocainized coca leaves or extractions which do not contain cocaine or ecgonine;

295 (e) Concentrate of poppy straw (the crude extract of poppy straw in either  
296 liquid, solid or powder form which contains the phenanthrene alkaloids of the

297 opium poppy);

298 (2) Any of the following opiates, including their isomers, esters, ethers,  
299 salts, and salts of isomers, whenever the existence of these isomers, esters, ethers  
300 and salts is possible within the specific chemical designation, dextrorphan and  
301 levopropoxyphene excepted:

- 302 (a) Alfentanil;
- 303 (b) Alphaprodine;
- 304 (c) Anileridine;
- 305 (d) Bezitramide;
- 306 (e) Bulk dextropropoxyphene;
- 307 (f) Carfentanil;
- 308 (g) Dihydrocodeine;
- 309 (h) Diphenoxylate;
- 310 (i) Fentanyl;
- 311 (j) Isomethadone;
- 312 (k) Levo-alphacetylmethadol;
- 313 (l) Levomethorphan;
- 314 (m) Levorphanol;
- 315 (n) Metazocine;
- 316 (o) Methadone;
- 317 (p) Meperidine;
- 318 (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4,  
319 4-diphenylbutane;
- 320 (r) Moramide-Intermediate, 2-methyl-3-morpholino-1,  
321 1-diphenylpropane—carboxylic acid;
- 322 (s) Pethidine (meperidine);
- 323 (t) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 324 (u) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 325 (v) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic  
326 acid;
- 327 (w) Phenazocine;
- 328 (x) Piminodine;
- 329 (y) Racemethorphan;
- 330 (z) Racemorphan;
- 331 (aa) Remifentanil;
- 332 (bb) Sufentanil;

- 333 (cc) Tapentadol;
- 334 (3) Any material, compound, mixture, or preparation which contains any  
335 quantity of the following substances having a stimulant effect on the central  
336 nervous system:
- 337 (a) Amphetamine, its salts, optical isomers, and salts of its optical  
338 isomers;
- 339 (b) Lisdexamphetamine, its salts, isomers, and salts of its isomers;
- 340 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
- 341 (d) Phenmetrazine and its salts;
- 342 (e) Methylphenidate;
- 343 (4) Any material, compound, mixture, or preparation which contains any  
344 quantity of the following substances having a depressant effect on the central  
345 nervous system, including its salts, isomers, and salts of isomers whenever the  
346 existence of those salts, isomers, and salts of isomers is possible within the  
347 specific chemical designation:
- 348 (a) Amobarbital;
- 349 (b) Glutethimide;
- 350 (c) Pentobarbital;
- 351 (d) Phencyclidine;
- 352 (e) Secobarbital;
- 353 (5) Any material or compound which contains any quantity of nabilone;
- 354 (6) Any material, compound, mixture, or preparation which contains any  
355 quantity of the following substances:
- 356 (a) Immediate precursor to amphetamine and methamphetamine:  
357 Phenylacetone;
- 358 (b) Immediate precursors to phencyclidine (PCP):
- 359 a. 1-phenylcyclohexylamine;
- 360 b. 1-piperidinocyclohexanecarbonitrile (PCC);
- 361 (7) Any material, compound, mixture, or preparation which contains any  
362 quantity of the following alkyl nitrites:
- 363 (a) Amyl nitrite;
- 364 (b) Butyl nitrite.
- 365 5. The department of health and senior services shall place a substance  
366 in Schedule III if it finds that:
- 367 (1) The substance has a potential for abuse less than the substances listed  
368 in Schedules I and II;

369 (2) The substance has currently accepted medical use in treatment in the  
370 United States; and

371 (3) Abuse of the substance may lead to moderate or low physical  
372 dependence or high psychological dependence.

373 6. The controlled substances listed in this subsection are included in  
374 Schedule III:

375 (1) Any material, compound, mixture, or preparation which contains any  
376 quantity of the following substances having a potential for abuse associated with  
377 a stimulant effect on the central nervous system:

378 (a) Benzphetamine;

379 (b) Chlorphentermine;

380 (c) Clortermine;

381 (d) Phendimetrazine;

382 (2) Any material, compound, mixture or preparation which contains any  
383 quantity or salt of the following substances or salts having a depressant effect on  
384 the central nervous system:

385 (a) Any material, compound, mixture or preparation which contains any  
386 quantity or salt of the following substances combined with one or more active  
387 medicinal ingredients:

388 a. Amobarbital;

389 b. Secobarbital;

390 c. Pentobarbital;

391 (b) Any suppository dosage form containing any quantity or salt of the  
392 following:

393 a. Amobarbital;

394 b. Secobarbital;

395 c. Pentobarbital;

396 (c) Any substance which contains any quantity of a derivative of  
397 barbituric acid or its salt;

398 (d) Chlorhexadol;

399 (e) Embutramide;

400 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers  
401 contained in a drug product for which an application has been approved under  
402 Section 505 of the federal Food, Drug, and Cosmetic Act;

403 (g) Ketamine, its salts, isomers, and salts of isomers;

404 (h) Lysergic acid;

- 405 (i) Lysergic acid amide;  
406 (j) Methypylon;  
407 (k) Sulfondiethylmethane;  
408 (l) Sulfonethylmethane;  
409 (m) Sulfonmethane;  
410 (n) Tiletamine and zolazepam or any salt thereof;  
411 (3) Nalorphine;  
412 (4) Any material, compound, mixture, or preparation containing limited  
413 quantities of any of the following narcotic drugs or their salts:  
414 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not  
415 more than ninety milligrams per dosage unit, with an equal or greater quantity  
416 of an isoquinoline alkaloid of opium;  
417 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not  
418 more than ninety milligrams per dosage unit with one or more active, nonnarcotic  
419 ingredients in recognized therapeutic amounts;  
420 (c) Not more than three hundred milligrams of hydrocodone per one  
421 hundred milliliters or not more than fifteen milligrams per dosage unit, with a  
422 fourfold or greater quantity of an isoquinoline alkaloid of opium;  
423 (d) Not more than three hundred milligrams of hydrocodone per one  
424 hundred milliliters or not more than fifteen milligrams per dosage unit, with one  
425 or more active nonnarcotic ingredients in recognized therapeutic amounts;  
426 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters  
427 or not more than ninety milligrams per dosage unit, with one or more active  
428 nonnarcotic ingredients in recognized therapeutic amounts;  
429 (f) Not more than three hundred milligrams of ethylmorphine per one  
430 hundred milliliters or not more than fifteen milligrams per dosage unit, with one  
431 or more active, nonnarcotic ingredients in recognized therapeutic amounts;  
432 (g) Not more than five hundred milligrams of opium per one hundred  
433 milliliters or per one hundred grams or not more than twenty-five milligrams per  
434 dosage unit, with one or more active nonnarcotic ingredients in recognized  
435 therapeutic amounts;  
436 (h) Not more than fifty milligrams of morphine per one hundred milliliters  
437 or per one hundred grams, with one or more active, nonnarcotic ingredients in  
438 recognized therapeutic amounts;  
439 (5) Any material, compound, mixture, or preparation containing any of the  
440 following narcotic drugs or their salts, as set forth in subdivision (6) of this

441 subsection; buprenorphine;

442 (6) Anabolic steroids. Any drug or hormonal substance, chemically and  
443 pharmacologically related to testosterone (other than estrogens, progestins,  
444 corticosteroids, and dehydroepiandrosterone) that promotes muscle growth, except  
445 an anabolic steroid which is expressly intended for administration through  
446 implants to cattle or other nonhuman species and which has been approved by  
447 the Secretary of Health and Human Services for that administration. If any  
448 person prescribes, dispenses, or distributes such steroid for human use, such  
449 person shall be considered to have prescribed, dispensed, or distributed an  
450 anabolic steroid within the meaning of this subdivision. Unless specifically  
451 excepted or unless listed in another schedule, any material, compound, mixture  
452 or preparation containing any quantity of the following substances, including its  
453 salts, esters and ethers:

- 454 (a)  $3\beta,17$ -dihydroxy-5 $\alpha$ -androstane;
- 455 (b) 3 $\alpha,17\beta$ -dihydroxy-5 $\alpha$ -androstane;
- 456 (c) 5 $\alpha$ -androstan-3,17-dione;
- 457 (d) 1-androstenediol ( $3\beta,17\beta$ -dihydroxy-5 $\alpha$ -androst-1-ene);
- 458 (e) 1-androstenediol (3 $\alpha,17\beta$ -dihydroxy-5 $\alpha$ -androst-1-ene);
- 459 (f) 4-androstenediol ( $3\beta,17\beta$ -dihydroxy-androst-4-ene);
- 460 (g) 5-androstenediol ( $3\beta,17\beta$ -dihydroxy-androst-5-ene);
- 461 (h) 1-androstenedione ([5 $\alpha$ ]-androst-1-en-3,17-dione);
- 462 (i) 4-androstenedione (androst-4-en-3,17-dione);
- 463 (j) 5-androstenedione (androst-5-en-3,17-dione);
- 464 (k) Bolasterone (7 $\alpha$ , 17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyandrost-4-en-3-one);
- 465 (l) Boldenone (17 $\beta$ -hydroxyandrost-1,4,-diene-3-one);
- 466 (m) Boldione;
- 467 (n) Calusterone (7 $\beta$ , 17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyandrost-4-en-3-one);
- 468 (o) Clostebol (4-chloro-17 $\beta$ -hydroxyandrost-4-en-3-one);
- 469 (p) Dehydrochloromethyltestosterone (4-chloro-17 $\beta$ -hydroxy-17 $\alpha$ -methyl-androst  
470 -1,4-dien-3-one);
- 471 (q) Desoxymethyltestosterone;
- 472 (r) ?1-dihydrotestosterone (a.k.a. '1-testosterone')(17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3  
473 -one);
- 474 (s) 4-dihydrotestosterone (17 $\beta$ -hydroxy-androstan-3-one);
- 475 (t) Drostanolone (17 $\beta$ -hydroxy-2 $\alpha$ -methyl-5 $\alpha$ -androstan-3-one);
- 476 (u) Ethylestrenol (17 $\alpha$ -ethyl-17 $\beta$ -hydroxyestr-4-ene);



- 477 (v) Fluoxymesterone (9-fluoro-17a-methyl-11 $\beta$ , 17 $\beta$ -dihydroxyandrost-4-  
478 en-3-one);
- 479 (w) Formebolone (2-formyl-17a-methyl-11a, 17 $\beta$ -dihydroxyandrost-1,4  
480 -dien-3-one);
- 481 (x) Furazabol (17a-methyl-17 $\beta$ -hydroxyandrostano[2,3-c]-furazan);
- 482 (y) 13 $\beta$ -ethyl-17 $\beta$ -hydroxygon-4-en-3-one;
- 483 (z) 4-hydroxytestosterone (4,17 $\beta$ -dihydroxy-androst-4-en-3-one);
- 484 (aa) 4-hydroxy-19-nortestosterone (4,17 $\beta$ -dihydroxy-estr-4-en-3-one);
- 485 (bb) Mestanolone (17a-methyl-17 $\beta$ -hydroxy-5-androstan-3-one);
- 486 (cc) Mesterolone (1a-methyl-17 $\beta$ -hydroxy-[5a]-androstan-3-one);
- 487 (dd) Methandienone (17a-methyl-17 $\beta$ -hydroxyandrost-1,4-dien-3-one);
- 488 (ee) Methandriol (17a-methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-5-ene);
- 489 (ff) Methenolone (1-methyl-17 $\beta$ -hydroxy-5a-androst-1-en-3-one);
- 490 (gg) 17a-methyl-3 $\beta$ ,17 $\beta$ -dihydroxy-5a-androstane);
- 491 (hh) 17a-methyl-3a,17 $\beta$ -dihydroxy-5a-androstane);
- 492 (ii) 17a-methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-4-ene;
- 493 (jj) 17a-methyl-4-hydroxynandrolone (17a-methyl-4-hydroxy -17 $\beta$ -hydroxyestr-  
494 4-en-3-one);
- 495 (kk) Methyldienolone (17a-methyl-17 $\beta$ -hydroxyestra-4,9(10)-dien-3-one);
- 496 (ll) Methyltrienolone (17a-methyl-17 $\beta$ -hydroxyestra-4,9-11-trien-3-one);
- 497 (mm) Methyltestosterone (17a-methyl-17 $\beta$ -hydroxyandrost-4-en-3-one);
- 498 (nn) Mibolerone (7a,17a-dimethyl-17 $\beta$ -hydroxyestr-4-en-3-one);
- 499 (oo) 17a-methyl-?1-dihydrotestosterone (17b $\beta$ -hydroxy-17a-methyl-5a-  
500 androst-1-en-3-one) (a.k.a. '17-a-methyl-1-testosterone');
- 501 (pp) Nandrolone (17 $\beta$ -hydroxyestr-4-ene-3-one);
- 502 (qq) 19-nor-4-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-4-ene);
- 503 (rr) 19-nor-4-androstenediol (3a,17 $\beta$ -dihydroxyestr-4-ene);
- 504 (ss) 19-nor-4,9(10)-androstadienedione;
- 505 (tt) 19-nor-5-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-5-ene);
- 506 (uu) 19-nor-5-androstenediol (3a,17 $\beta$ -dihydroxyestr-5-ene);
- 507 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
- 508 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 509 (xx) Norbolethone (13 $\beta$ ,17a-diethyl-17 $\beta$ -hydroxygon-4-en-3-one);
- 510 (yy) Norclostebol (4-chloro-17 $\beta$ -hydroxyestr-4-en-3-one);
- 511 (zz) Norethandrolone (17a-ethyl-17 $\beta$ -hydroxyestr-4-en-3-one);
- 512 (aaa) Normethandrolone (17a-methyl-17 $\beta$ -hydroxyestr-4-en-3-one);

- 513 (bbb) Oxandrolone (17a-methyl-17 $\beta$ -hydroxy-2-oxa-[5a]-androstan-3-one);  
514 (ccc) Oxymesterone (17a-methyl-4,17 $\beta$ -dihydroxyandrost-4-en-3-one);  
515 (ddd) Oxymethalone (17a-methyl-2-hydroxymethylene-17 $\beta$ -hydroxy  
516 -[5a]-androstan-3-one);  
517 (eee) Stanozolol (17a-methyl-17 $\beta$ -hydroxy-[5a]-androst-2-eno[3,2-c]-pyrazole);  
518 (fff) Stenbolone (17 $\beta$ -hydroxy-2-methyl-[5a]-androst-1-en-3-one);  
519 (ggg) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic  
520 acid lactone);  
521 (hhh) Testosterone (17 $\beta$ -hydroxyandrost-4-en-3-one);  
522 (iii) Tetrahydrogestrinone (13 $\beta$ ,17a-diethyl-17 $\beta$ -hydroxygon-4, 9,11-trien-3-one);  
523 (jjj) Trenbolone (17 $\beta$ -hydroxyestr-4,9,11-trien-3-one);  
524 (kkk) Any salt, ester, or ether of a drug or substance described or listed  
525 in this subdivision, except an anabolic steroid which is expressly intended for  
526 administration through implants to cattle or other nonhuman species and which  
527 has been approved by the Secretary of Health and Human Services for that  
528 administration;
- 529 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin  
530 capsule in a United States Food and Drug Administration approved drug product;
- 531 (8) The department of health and senior services may except by rule any  
532 compound, mixture, or preparation containing any stimulant or depressant  
533 substance listed in subdivisions (1) and (2) of this subsection from the application  
534 of all or any part of sections 195.010 to 195.320 if the compound, mixture, or  
535 preparation contains one or more active medicinal ingredients not having a  
536 stimulant or depressant effect on the central nervous system, and if the  
537 admixtures are included therein in combinations, quantity, proportion, or  
538 concentration that vitiate the potential for abuse of the substances which have  
539 a stimulant or depressant effect on the central nervous system.
- 540 7. The department of health and senior services shall place a substance  
541 in Schedule IV if it finds that:
- 542 (1) The substance has a low potential for abuse relative to substances in  
543 Schedule III;
- 544 (2) The substance has currently accepted medical use in treatment in the  
545 United States; and
- 546 (3) Abuse of the substance may lead to limited physical dependence or  
547 psychological dependence relative to the substances in Schedule III.
- 548 8. The controlled substances listed in this subsection are included in

## 549 Schedule IV:

550 (1) Any material, compound, mixture, or preparation containing any of the  
551 following narcotic drugs or their salts calculated as the free anhydrous base or  
552 alkaloid, in limited quantities as set forth below:

553 (a) Not more than one milligram of difenoxin and not less than twenty-five  
554 micrograms of atropine sulfate per dosage unit;

555 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,  
556 2-diphenyl-3-methyl-2-propionoxybutane);

557 (c) Any of the following limited quantities of narcotic drugs or their salts,  
558 which shall include one or more nonnarcotic active medicinal ingredients in  
559 sufficient proportion to confer upon the compound, mixture or preparation  
560 valuable medicinal qualities other than those possessed by the narcotic drug  
561 alone:

562 a. Not more than two hundred milligrams of codeine per one hundred  
563 milliliters or per one hundred grams;

564 b. Not more than one hundred milligrams of dihydrocodeine per one  
565 hundred milliliters or per one hundred grams;

566 c. Not more than one hundred milligrams of ethylmorphine per one  
567 hundred milliliters or per one hundred grams;

568 (2) Any material, compound, mixture or preparation containing any  
569 quantity of the following substances, including their salts, isomers, and salts of  
570 isomers whenever the existence of those salts, isomers, and salts of isomers is  
571 possible within the specific chemical designation:

572 (a) Alprazolam;

573 (b) Barbital;

574 (c) Bromazepam;

575 (d) Camazepam;

576 (e) Chloral betaine;

577 (f) Chloral hydrate;

578 (g) Chlordiazepoxide;

579 (h) Clobazam;

580 (i) Clonazepam;

581 (j) Clorazepate;

582 (k) Clotiazepam;

583 (l) Cloxazolam;

584 (m) Delorazepam;

- 585 (n) Diazepam;  
586 (o) Dichloralphenazone;  
587 (p) Estazolam;  
588 (q) Ethchlorvynol;  
589 (r) Ethinamate;  
590 (s) Ethyl loflazepate;  
591 (t) Fludiazepam;  
592 (u) Flunitrazepam;  
593 (v) Flurazepam;  
594 (w) Fospropofol;  
595 (x) Halazepam;  
596 (y) Haloxazolam;  
597 (z) Ketazolam;  
598 (aa) Loprazolam;  
599 (bb) Lorazepam;  
600 (cc) Lormetazepam;  
601 (dd) Mebutamate;  
602 (ee) Medazepam;  
603 (ff) Meprobamate;  
604 (gg) Methohexital;  
605 (hh) Methylphenobarbital (mephobarbital);  
606 (ii) Midazolam;  
607 (jj) Nimetazepam;  
608 (kk) Nitrazepam;  
609 (ll) Nordiazepam;  
610 (mm) Oxazepam;  
611 (nn) Oxazolam;  
612 (oo) Paraldehyde;  
613 (pp) Petrichloral;  
614 (qq) Phenobarbital;  
615 (rr) Pinazepam;  
616 (ss) Prazepam;  
617 (tt) Quazepam;  
618 (uu) Temazepam;  
619 (vv) Tetrazepam;  
620 (ww) Triazolam;

621 (xx) Zaleplon;  
622 (yy) Zolpidem;  
623 (zz) Zopiclone;  
624 (3) Any material, compound, mixture, or preparation which contains any  
625 quantity of the following substance including its salts, isomers and salts of  
626 isomers whenever the existence of such salts, isomers and salts of isomers is  
627 possible: fenfluramine;  
628 (4) Any material, compound, mixture or preparation containing any  
629 quantity of the following substances having a stimulant effect on the central  
630 nervous system, including their salts, isomers and salts of isomers:  
631 (a) Cathine ((+)-norpseudoephedrine);  
632 (b) Diethylpropion;  
633 (c) Fencamfamin;  
634 (d) Fenproporex;  
635 (e) Mazindol;  
636 (f) Mefenorex;  
637 (g) Modafinil;  
638 (h) Pemoline, including organometallic complexes and chelates thereof;  
639 (i) Phentermine;  
640 (j) Pipradrol;  
641 (k) Sibutramine;  
642 (l) SPA ((-)-1-dimethyamino-1,2-diphenylethane);  
643 (5) Any material, compound, mixture or preparation containing any  
644 quantity of the following substance, including its salts:  
645 (a) butorphanol;  
646 (b) pentazocine;  
647 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when  
648 the substance is the only active medicinal ingredient;  
649 (7) The department of health and senior services may except by rule any  
650 compound, mixture, or preparation containing any depressant substance listed in  
651 subdivision (1) of this subsection from the application of all or any part of sections  
652 195.010 to 195.320 and sections 579.015 to 579.086 if the compound, mixture, or  
653 preparation contains one or more active medicinal ingredients not having a  
654 depressant effect on the central nervous system, and if the admixtures are  
655 included therein in combinations, quantity, proportion, or concentration that  
656 vitiate the potential for abuse of the substances which have a depressant effect

657 on the central nervous system.

658 9. The department of health and senior services shall place a substance  
659 in Schedule V if it finds that:

660 (1) The substance has low potential for abuse relative to the controlled  
661 substances listed in Schedule IV;

662 (2) The substance has currently accepted medical use in treatment in the  
663 United States; and

664 (3) The substance has limited physical dependence or psychological  
665 dependence liability relative to the controlled substances listed in Schedule IV.

666 10. The controlled substances listed in this subsection are included in  
667 Schedule V:

668 (1) Any compound, mixture or preparation containing any of the following  
669 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in  
670 limited quantities as set forth below, which also contains one or more nonnarcotic  
671 active medicinal ingredients in sufficient proportion to confer upon the compound,  
672 mixture or preparation valuable medicinal qualities other than those possessed  
673 by the narcotic drug alone:

674 (a) Not more than two and five-tenths milligrams of diphenoxylate and not  
675 less than twenty-five micrograms of atropine sulfate per dosage unit;

676 (b) Not more than one hundred milligrams of opium per one hundred  
677 milliliters or per one hundred grams;

678 (c) Not more than five-tenths milligram of difenoxin and not less than  
679 twenty-five micrograms of atropine sulfate per dosage unit;

680 (2) Any material, compound, mixture or preparation which contains any  
681 quantity of the following substance having a stimulant effect on the central  
682 nervous system including its salts, isomers and salts of isomers: pyrovalerone;

683 (3) Any compound, mixture, or preparation containing any detectable  
684 quantity of pseudoephedrine or its salts or optical isomers, or salts of optical  
685 isomers or any compound, mixture, or preparation containing any detectable  
686 quantity of ephedrine or its salts or optical isomers, or salts of optical isomers;

687 (4) Unless specifically exempted or excluded or unless listed in another  
688 schedule, any material, compound, mixture, or preparation which contains any  
689 quantity of the following substances having a depressant effect on the central  
690 nervous system, including its salts:

691 (a) Lacosamide;

692 (b) Pregabalin.

693           11. If any compound, mixture, or preparation as specified in subdivision  
694 (3) of subsection 10 of this section is dispensed, sold, or distributed in a pharmacy  
695 without a prescription:

696           (1) All packages of any compound, mixture, or preparation containing any  
697 detectable quantity of pseudoephedrine, its salts or optical isomers, or salts of  
698 optical isomers or ephedrine, its salts or optical isomers, or salts of optical  
699 isomers, shall be offered for sale only from behind a pharmacy counter where the  
700 public is not permitted, and only by a registered pharmacist or registered  
701 pharmacy technician; and

702           (2) Any person purchasing, receiving or otherwise acquiring any  
703 compound, mixture, or preparation containing any detectable quantity of  
704 pseudoephedrine, its salts or optical isomers, or salts of optical isomers or  
705 ephedrine, its salts or optical isomers, or salts of optical isomers shall be at least  
706 eighteen years of age; and

707           (3) The pharmacist, intern pharmacist, or registered pharmacy technician  
708 shall require any person, prior to such person's purchasing, receiving or otherwise  
709 acquiring such compound, mixture, or preparation to furnish suitable photo  
710 identification that is issued by a state or the federal government or a document  
711 that, with respect to identification, is considered acceptable and showing the date  
712 of birth of the person;

713           (4) The seller shall deliver the product directly into the custody of the  
714 purchaser.

715           12. Pharmacists, intern pharmacists, and registered pharmacy technicians  
716 shall implement and maintain an electronic log of each transaction. Such log  
717 shall include the following information:

718           (1) The name, address, and signature of the purchaser;

719           (2) The amount of the compound, mixture, or preparation purchased;

720           (3) The date and time of each purchase; and

721           (4) The name or initials of the pharmacist, intern pharmacist, or  
722 registered pharmacy technician who dispensed the compound, mixture, or  
723 preparation to the purchaser.

724           13. Each pharmacy shall submit information regarding sales of any  
725 compound, mixture, or preparation as specified in subdivision (3) of subsection 10  
726 of this section in accordance with transmission methods and frequency  
727 established by the department by regulation;

728           14. No person shall dispense, sell, purchase, receive, or otherwise acquire

quantities greater than those specified in this chapter.

15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products in a pharmacy shall ensure that all such products are located only behind a pharmacy counter where the public is not permitted.

16. The penalties for a knowing or reckless violation of the provisions of subsections 11 to 15 of this section are found in section 579.060.

17. The scheduling of substances specified in subdivision (3) of subsection 10 of this section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds, mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound, mixture, or preparation specified in subdivision (3) of subsection 10 of this section which must be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.

18. The manufacturer of a drug product or another interested party may apply with the department of health and senior services for an exemption from this section. The department of health and senior services may grant an exemption by rule from this section if the department finds the drug product is not used in the illegal manufacture of methamphetamine or other controlled or dangerous substances. The department of health and senior services shall rely on reports from law enforcement and law enforcement evidentiary laboratories in determining if the proposed product can be used to manufacture illicit controlled substances.

19. The department of health and senior services shall revise and republish the schedules annually.

20. The department of health and senior services shall promulgate rules under chapter 536 regarding the security and storage of Schedule V controlled substances, as described in subdivision (3) of subsection 10 of this section, for distributors as registered by the department of health and senior services.

21. Logs of transactions required to be kept and maintained by this section and section 195.417 shall create a rebuttable presumption that the person whose name appears in the logs is the person whose transactions are recorded in the logs.

**195.600. 1. Sections 195.600 to 195.606 shall be known as the "Industrial Hemp Pilot Program Act".**

**2. For the purposes of sections 195.600 to 195.606, the following terms shall mean:**

**(1) "Agricultural hemp seed", cannabis sativa seed that meets any**



6 labeling, quality, or other standards set by the department of  
7 agriculture and that is intended for sale, is sold to, or is purchased by  
8 licensed growers for planting;

9 (2) "Crop", any contiguous field of industrial hemp grown under  
10 a single license;

11 (3) "Department", the Missouri department of agriculture;

12 (4) "Grower", a person, joint venture, or cooperative that  
13 produces industrial hemp;

14 (5) "Handler", a person, joint venture, or cooperative that  
15 receives industrial hemp for processing into commodities, products, or  
16 agricultural hemp seed;

17 (6) "Industrial hemp", the same as such term is defined in section  
18 195.010;

19 (7) "Industrial hemp plant monitoring system", an electronic  
20 seed-to-sale tracking system that includes, but is not limited to, testing  
21 and data collection established and maintained by a grower or handler  
22 and available to the department for purposes of documenting and for  
23 monitoring agricultural hemp seed and industrial hemp plant  
24 development throughout the life cycle of an industrial hemp plant  
25 cultivated as an agricultural product from seed planting to final  
26 packaging.

195.603. 1. Industrial hemp production, possession, and  
2 commerce in industrial hemp commodities and products shall be  
3 permitted in this state under sections 195.600 to 195.606.

4 2. Industrial hemp shall be an agricultural product that is  
5 subject to regulation by the department of agriculture, including  
6 compliance with an industrial hemp plant monitoring system. Any  
7 grower and handler of industrial hemp shall obtain a license from the  
8 department. Growers and handlers engaged in the production of  
9 agricultural hemp seed also shall have an agricultural hemp seed  
10 production permit.

11 3. An application for an industrial hemp license or agricultural  
12 hemp seed production permit shall include:

13 (1) The name and address of the applicant;

14 (2) The name and address of the industrial hemp operation of the  
15 applicant;

16 (3) The global positioning system coordinates and legal

17 description for the property used for the industrial hemp;

18 (4) If the industrial hemp license or agricultural hemp seed  
19 production permit application is by the grower, information sufficient  
20 to establish that the industrial hemp crop of the applicant will be at  
21 least two and one-half acres in size; and

22 (5) The application fee, as determined by the department, in an  
23 amount sufficient to cover the administrative costs of processing  
24 license and permit applications and conducting criminal history  
25 background checks; and

26 (6) Any other information required by the department.

27 4. The department shall issue a license or permit under this  
28 section to an applicant who meets the requirements of sections 195.600  
29 to 195.606 and upon satisfactory completion of a fingerprint criminal  
30 history background check.

31 5. Upon issuance of a license or permit, information regarding  
32 all license and permit holders shall be forwarded to the state highway  
33 patrol.

34 6. An industrial hemp license or agricultural hemp seed  
35 production permit is:

36 (1) Nontransferable; except that, such license or permit may be  
37 transferred to a spouse, child, or stepchild of the license or permit  
38 holder who may operate under the existing license or permit until the  
39 registration expires, at which time the renewal shall reflect the change  
40 in licensee;

41 (2) Valid for a three-year term unless revoked by the department;  
42 and

43 (3) May be renewed as determined by the department.

44 7. An agricultural hemp seed production permit authorizes a  
45 grower or handler to produce and handle agricultural hemp seed for  
46 sale to licensed industrial hemp growers and handlers. The department  
47 shall make information that identifies sellers of agricultural hemp seed  
48 available to growers, and any seller of agricultural hemp seed shall  
49 ensure that the seed complies with any standards established by the  
50 department.

51 8. A grower may retain seed from each industrial hemp crop to  
52 ensure a sufficient supply of seed for that grower for the following  
53 year. A grower shall not be required to obtain an agricultural hemp

54 seed production permit in order to retain seed for future planting. Any  
55 seed retained by a grower for future planting shall not be sold or  
56 transferred and does not have to meet agricultural hemp seed  
57 standards established by the department.

58       9. Every grower or handler shall be subject to an industrial hemp  
59 plant monitoring system and shall keep industrial hemp crop and  
60 agricultural hemp seed records as required by the department. Upon  
61 three days' notice, the department may require an inspection or audit  
62 during any normal business hours for the purpose of ensuring  
63 compliance with:

- 64       (1) Any provision of this chapter;
- 65       (2) Department rules and regulations;
- 66       (3) Industrial hemp license or agricultural hemp seed production  
67 permit requirements, terms, or conditions;
- 68       (4) Any industrial hemp plant monitoring system; or
- 69       (5) A final department order directed to the grower's or handler's  
70 industrial hemp operations or activities.

71       10. In addition to any inspection conducted under subsection 9  
72 of this section, the department may inspect any industrial hemp crop  
73 during the crop's growth phase and take a representative composite  
74 sample for field analysis. If a crop contains an average  
75 tetrahydrocannabinol concentration exceeding three-tenths of one  
76 percent on a dry weight basis, the department may detain, seize, or  
77 embargo the crop. The department may contract with the University  
78 of Missouri agriculture and natural resources extension for inspection  
79 services provided under sections 195.600 to 195.606.

80       11. The department may charge growers and handlers reasonable  
81 fees as determined by the department for the purpose of carrying out  
82 the duties of the department under sections 195.600 to 195.606. The  
83 grower or handler shall pay the cost of any inspection of the grower or  
84 handler ordered by the department. All fees collected under sections  
85 195.600 to 195.606 shall be deposited in a dedicated fund for use by the  
86 department to carry out the duties of the department under sections  
87 195.600 to 195.606.

88       12. The department shall promulgate rules necessary to  
89 administer the provisions of sections 195.600 to 195.606 by March 30,  
90 2018. Any rule or portion of a rule, as that term is defined in section

91 536.010, that is created under the authority delegated in this section  
92 shall become effective only if it complies with and is subject to all of  
93 the provisions of chapter 536 and, if applicable, section  
94 536.028. Sections 195.600 to 195.606 and chapter 536 are nonseverable,  
95 and if any of the powers vested with the general assembly under  
96 chapter 536 to review, to delay the effective date, or to disapprove and  
97 annul a rule are subsequently held unconstitutional, then the grant of  
98 rulemaking authority and any rule proposed or adopted after August  
99 28, 2017, shall be invalid and void.

100 13. By September 30, 2017, the department shall establish a  
101 committee to advise the department on appropriate rules and  
102 regulations to implement the industrial hemp pilot program. The  
103 committee shall be administered and its members chosen by the  
104 director of the department.

105 14. The committee shall:

- 106 (1) Review policies in other states regarding industrial hemp;  
107 (2) Determine best practices for the production of industrial  
108 hemp and the licensure of growers; and  
109 (3) Research and draft rules and regulations regarding industrial  
110 hemp and the pilot program.

111 15. The committee shall be comprised of a representative from  
112 each of the following:

- 113 (1) The agricultural programs at Lincoln University and the  
114 Columbia campus of the University of Missouri;  
115 (2) The governor's office;  
116 (3) The Missouri state highway patrol;  
117 (4) The Missouri sheriffs association;  
118 (5) An association advocating for farmers;  
119 (6) An association advocating for industrial hemp; and  
120 (7) The Missouri Crop Improvement Association.

121 16. The committee may also include other members or  
122 workgroups deemed necessary to accomplish its purposes, including  
123 but not limited to representatives from state agencies, local advisory  
124 groups and community members, and members of the general assembly.

125 17. The committee shall be dissolved April 1, 2018, but may be  
126 reconvened as needed by the department to assist in the promulgation  
127 and amendment of rules under this section.

195.606. 1. The department may revoke or refuse to issue or  
2 renew an industrial hemp license or agricultural hemp seed production  
3 permit and may impose a civil penalty of not less than two thousand  
4 five hundred dollars or more than fifty thousand dollars for violation  
5 of:

6 (1) A license or permit requirement, term, or condition;

7 (2) Department rules relating to growing or handling industrial  
8 hemp;

9 (3) Any industrial hemp plant monitoring system; or

10 (4) A final order of the department that is specifically directed  
11 to the grower's or handler's industrial hemp operations or activities.

12 2. In addition, the department may revoke or refuse to issue or  
13 renew an industrial hemp license or an agricultural hemp seed  
14 production permit for failing to comply with any provision of this  
15 chapter or for a violation of any rule of the department that pertains  
16 to agricultural operations or activities other than industrial hemp  
17 growing or handling.

195.609. 1. Any person growing industrial hemp who does not  
2 have a valid industrial hemp license issued under sections 195.600 to  
3 195.606 shall be subject to an administrative fine of five hundred  
4 dollars and shall obtain a valid license to grow industrial hemp within  
5 thirty days.

6 2. If during the thirty-day period described in subsection 1 of  
7 this section such person applies for and receives an industrial hemp  
8 license, the amount of the fine imposed under subsection 1 of this  
9 section shall be refunded in full.

10 3. If during the thirty-day period described in subsection 1 of  
11 this section such person fails to obtain an industrial hemp license, the  
12 person shall be fined one thousand dollars per day until such person  
13 obtains a license to grow industrial hemp or the person's industrial  
14 hemp crop is destroyed.

✓